- Report
- August 2025
Global
From €4324EUR$4,900USD£3,739GBP
- Clinical Trials
- April 2025
- 40 Pages
Global
From €1103EUR$1,250USD£954GBP
- Report
- January 2025
- 175 Pages
Global
From €3962EUR$4,490USD£3,427GBP
- Report
- June 2025
- 150 Pages
Global
From €2382EUR$2,699USD£2,060GBP
- Report
- June 2024
- 200 Pages
Global
From €7015EUR$7,950USD£6,067GBP
- Report
- May 2024
- 134 Pages
Global
From €5735EUR$6,499USD£4,960GBP
- Report
- May 2024
- 187 Pages
Global
From €3971EUR$4,500USD£3,434GBP
- Report
- July 2022
- 71 Pages
Global
From €1765EUR$2,000USD£1,526GBP
The Hepatitis D Drug market is a subset of the Infectious Diseases Drugs market, focusing on treatments for the Hepatitis D virus. This virus is a serious infection of the liver, and is often contracted in conjunction with the Hepatitis B virus. Treatment for Hepatitis D is typically a combination of antiviral medications and supportive care. These medications are designed to reduce the amount of virus in the body, and to reduce the risk of complications.
The Hepatitis D Drug market is highly competitive, with a number of companies offering treatments for the virus. Some of the major players in the market include Gilead Sciences, AbbVie, Merck, and Bristol-Myers Squibb. These companies offer a range of treatments, including antiviral medications, vaccines, and supportive care. Show Less Read more
